The landscape of diabetes management in the United States is standing on the precipice of a monumental shift as the Centers for Medicare and Medicaid Services (CMS) prepares to decide on the expansion of coverage for continuous glucose monitors (CGMs). For years, these wearable sensors, which provide real-time blood sugar readings to smartphones or dedicated receivers, have been primarily reserved for patients with Type 1 diabetes or those with Type 2 diabetes who require intensive insulin therapy. However, emerging clinical data and shifting healthcare priorities have prompted a reevaluation of this policy. Industry leaders Dexcom and Abbott, the two dominant players in the CGM market, are now positioning themselves for what could be the largest expansion of their addressable market in history: the inclusion of millions of Type 2 diabetes patients who do not currently use insulin.
The Current Regulatory and Reimbursement Environment
As of late 2024, Medicare coverage for CGMs is governed by specific criteria that require a patient to have a diagnosis of diabetes and either be treated with insulin or have a documented history of severe hypoglycemia (dangerously low blood sugar). While this was a significant expansion from earlier years—when patients were required to perform at least four finger-stick tests a day and inject insulin multiple times daily—it still excludes a massive portion of the diabetic population. Specifically, those who manage their condition through diet, exercise, or oral medications like metformin and GLP-1 agonists currently lack a clear pathway to federal reimbursement for these devices.
The upcoming decision by the CMS, which Dexcom CEO Jake Leach expects to be announced before the end of 2024, aims to bridge this gap. If the CMS moves forward with the expansion, the policy is anticipated to go into effect by mid-2027. This timeline allows for the administrative and logistical infrastructure to be established, ensuring that healthcare providers and distributors can handle the influx of millions of new eligible beneficiaries.
Quantifying the Market Opportunity: 25 Million and Growing
The scale of the potential market expansion is difficult to overstate. According to estimates provided by Dexcom, approximately 25 million people in the United States live with Type 2 diabetes and do not take insulin. This demographic represents the "basal-only" or "non-insulin" segment that has long been the next frontier for medtech innovation. Within this group, roughly half—about 12.5 million people—are of Medicare age.
Abbott CEO Robert Ford offered a similar assessment during a July earnings call, noting that a favorable CMS decision could immediately make 10 million more Medicare recipients eligible for the technology. Beyond the direct impact of federal coverage, a CMS decision often serves as a catalyst for private commercial insurers. Historically, when Medicare expands coverage for a medical device or procedure, private payers like UnitedHealthcare, Aetna, and Cigna follow suit to maintain competitive benefits and adhere to evolving standards of care. This "halo effect" could potentially open the door for the remaining 12.5 million non-Medicare patients in the non-insulin Type 2 category.
Clinical Evidence: The Catalyst for Policy Change
The push for expanded coverage is not merely a corporate endeavor; it is backed by a growing body of clinical evidence suggesting that CGMs provide significant health benefits even for those not at risk of immediate insulin-related hypoglycemia. At the American Diabetes Association’s (ADA) 84th Scientific Sessions held earlier this summer, Dexcom presented results from a 26-week randomized, controlled trial that focused specifically on the non-insulin Type 2 population.
The study’s findings were compelling. Participants using a CGM demonstrated a significantly larger reduction in hemoglobin A1C—a measure of average blood sugar over three months—compared to a control group using traditional finger-stick methods. Furthermore, the CGM group spent an average of five more hours per day within a "normal" glucose range (70–180 mg/dL).
The clinical logic behind using CGMs for non-insulin patients centers on behavioral modification. Unlike a finger-stick, which provides a single data point in time, a CGM shows the user how specific foods, physical activities, and stress levels affect their blood sugar in real-time. This "biofeedback loop" allows patients to make immediate lifestyle adjustments, potentially slowing the progression of the disease and delaying or even preventing the need for insulin therapy. For the CMS, the long-term cost savings associated with preventing diabetes complications—such as kidney failure, blindness, and cardiovascular disease—could far outweigh the upfront cost of the sensors.
Competitive Strategies: Dexcom vs. Abbott
As the CMS decision looms, both Dexcom and Abbott are aggressively preparing their commercial infrastructures. While they share the same goal of market expansion, their strategies reflect their different corporate profiles.
Dexcom, a company solely focused on glucose monitoring, has doubled down on its technological integration. Its flagship G7 sensor is known for its high accuracy and integration with automated insulin delivery (AID) systems. However, for the non-insulin market, Dexcom recently launched "Stelo," the first glucose biosensor cleared by the FDA for over-the-counter (OTC) use. Stelo is specifically designed for Type 2 patients who do not use insulin, featuring a software interface that focuses on lifestyle insights rather than the clinical alerts required for insulin users. By creating a distinct product for this segment, Dexcom aims to capture the "wellness" and "early-intervention" markets while simultaneously pursuing Medicare reimbursement for its more clinical offerings.
Abbott, a diversified healthcare giant, leverages its massive global distribution network and the brand recognition of its FreeStyle Libre line. Robert Ford noted that the company is currently "preparing its sales force, distribution, and other resources" to capitalize on the Medicare expansion. Abbott’s FreeStyle Libre 3 is currently the smallest and thinnest sensor on the market, a form factor that appeals to Type 2 patients who may be more sensitive to the stigma of wearing a medical device. Abbott also recently received FDA clearance for "Lingo," its own consumer-facing biowearable, which will compete directly with Dexcom’s Stelo in the cash-pay and OTC space.
Financial Trajectory and Investor Outlook
The financial stakes are enormous. Abbott’s diabetes care division reported sales of $2.19 billion in the second quarter of 2024, representing a 10.5% year-over-year increase. Dexcom reported $1.31 billion in sales for the same period, a 13% increase. While these growth rates are healthy, both companies saw their stock prices fluctuate as investors weighed the potential for a temporary slowdown in the core insulin-using market against the massive upside of the non-insulin expansion.
Robert Ford described the potential CMS decision as a "multibillion-dollar opportunity" that could begin to materialize as early as this fall. For Dexcom, which has a smaller revenue base than Abbott, the impact of a 12.5-million-person market expansion could be transformative for its long-term valuation. Analysts suggest that even a modest 10% penetration into the non-insulin Medicare population could add hundreds of millions of dollars in recurring annual revenue for these firms.
Timeline of Key Milestones
To understand the current momentum, it is helpful to look at the chronology of CGM coverage evolution:
- 2017: CMS first grants coverage for "therapeutic" CGMs for patients who perform frequent testing and multiple daily injections.
- 2021: CMS eliminates the requirement for "frequent testing," simplifying the pathway for insulin-dependent patients.
- 2023: Coverage is expanded to include all people with diabetes who use any amount of insulin, as well as certain non-insulin users with a history of hypoglycemia.
- Summer 2024: Dexcom and Abbott present clinical data at the ADA Scientific Sessions supporting CGM use for all Type 2 patients.
- Late 2024 (Expected): CMS to issue a draft or final National Coverage Determination (NCD) regarding non-insulin Type 2 patients.
- Mid-2027 (Expected): Full implementation of the expanded coverage, allowing for widespread Medicare billing.
Broader Implications for the Healthcare System
The potential expansion of CGM coverage to the non-insulin Type 2 population represents a shift in the American healthcare philosophy from reactive treatment to proactive management. Type 2 diabetes is a progressive disease; many patients who start on oral medications eventually require insulin as their beta-cell function declines. By providing these patients with CGMs early in their diagnosis, the healthcare system is betting that better glycemic control will "flatten the curve" of disease progression.
Furthermore, this move could address significant health disparities. Data shows that minority and low-income populations are disproportionately affected by Type 2 diabetes and often have less access to advanced medical technology. A broad Medicare mandate would ensure that a patient’s socioeconomic status—or their specific type of health insurance—does not dictate their access to tools that are increasingly seen as the gold standard for diabetes care.
However, challenges remain. The sheer volume of data generated by millions of new CGM users could overwhelm primary care physicians, who are already stretched thin. Integrating CGM data into Electronic Health Records (EHRs) in a way that is actionable for doctors without being burdensome will be a critical hurdle for Dexcom and Abbott to clear.
As the industry waits for the CMS to signal its intent, the message from the medtech sector is clear: the era of the finger-stick is ending, and the era of continuous, data-driven metabolic health is just beginning. Whether the CMS decision comes in October or December, the trajectory of diabetes care in the United States has been irrevocably altered toward a future where every patient, regardless of their insulin status, has the data they need to manage their health in real-time.
